EGF receptor as a therapeutic target

被引：46

作者：

Levitzki, A ^{[1
]}

机构：

[1] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cell Signaling, IL-91904 Jerusalem, Israel

来源：

LUNG CANCER | 2003年 / 41卷

关键词：

EGFR; Her-2; tyrphostins; lung cancer;

D O I：

10.1016/S0169-5002(03)00134-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a rote in lung cancers, with special emphasis on the way EGFR/ Her-2 signaling cooperates with other signaling pathways. (C) 2003 Elsevier Science Ireland Ltd and Ainerican Society of Clinical Oncology. Published by Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：S9 / S14

页数：6

共 39 条

[1] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions [J].

Alroy, I ;

Yarden, Y .

FEBS LETTERS, 1997, 410 (01) :83-86

[2]

Arteaga CL, 2002, ONCOLOGIST, V7, P31

[3] HER-targeted tyrosine-kinase inhibitors [J].

Baselga, J ;

Hammond, LA .

ONCOLOGY, 2002, 63 :6-16

[4]

Baselga J, 2002, ONCOLOGIST, V7, P2

[5] Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase [J].

Bonasera, TA ;

Ortu, G ;

Rozen, Y ;

Krais, R ;

Freedman, NMT ;

Chisin, R ;

Gazit, A ;

Levitzki, A ;

Mishani, E .

NUCLEAR MEDICINE AND BIOLOGY, 2001, 28 (04) :359-374

[6]

Bridges AJ, 1999, CURR MED CHEM, V6, P825

[7]

Brognard J, 2001, CANCER RES, V61, P3986

[8]

Ciardiello F, 2002, TUMORI J, pS31

[9]

Ciardiello F, 2000, CLIN CANCER RES, V6, P2053

[10]

CIARDIELLO F, 2000, TUMORI, V88, pS155

← 1 2 3 4 →